Dosing of glucocorticoid (triamcinolone hexacetonid) when injecting knee joints of rheumatic diseases

Dosing of intraarticular triamcinolone hexacetonid for knee synovitis in chronic polyarthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-000993-20-SE

Enrollment

160

Registered

2014-09-02

Start date

2014-12-04

Completion date

Unknown

Last updated

2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic arthritis and rheumatoid arthritis with synovitis of the knee

Interventions

Trade Name: triamcinolone hexacetonide (Lederspan) Product Name: triamcinolone hexacetonid (Lederspan) Product Code: 9512 Pharmaceutical Form: Injection Trade Name: triamcinolone hexacetonide (Leders

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age > 18 years chronic polyarthritis (psoriatic arthritis or rheumatoid arthritis) Synovitis of the knee acceptance to participate in the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 100 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 60

Exclusion criteria

Exclusion criteria: prednisolone >10mg daily intraarticular glucocorticoid injection in this joint the past 3 months untreated ongoing infection severely disabled knee joint surgery performed or planned for this joint inability to understand study information

Design outcomes

Primary

Measure	Time frame
Main Objective: To study the relapse rate after intraaarticular triamcinolone hexacetonide (20 vs 40 mg) treatment for knee synovitis in patients with rheumatoid arthritis and psoriatic arthritis;Secondary Objective: Not applicable;Primary end point(s): Recurrence of knee symptoms and confirmed synovitis on a clinical examination ;Timepoint(s) of evaluation of this end point: At relapse , during visits according to clinical routines and a phone call after 6 months	—

Measure

Time frame

Main Objective: To study the relapse rate after intraaarticular triamcinolone hexacetonide (20 vs 40 mg) treatment for knee synovitis in patients with rheumatoid arthritis and psoriatic arthritis;Secondary Objective: Not applicable;Primary end point(s): Recurrence of knee symptoms and confirmed synovitis on a clinical examination ;Timepoint(s) of evaluation of this end point: At relapse , during visits according to clinical routines and a phone call after 6 months

—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026